StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Earnings

Myriad Genetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$202.70M
-1.5% on a year earlier
Adjusted Income (Loss) Per Share, Q3 FY2026
-$0.11
$0.00 a year earlier
Latest guidance
Lowered
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Myriad Genetics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$202.70M-1.5%-$0.46-$0.11Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$190.70M-10.5%-$0.46-$0.25Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$200.40M+2.2%-$0.36-$0.09Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026after the close$209.80M-0.6%-$0.08$0.04Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025after the close$205.70M-3.4%-$0.29$0.00Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$213.10M+0.5%-$3.57$0.05Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$196.00M-3.0%$0.00-$0.03Release
Q4 FY2024ended Dec 31, 2024Feb 24, 2025after the close$211.00M+7.1%-$0.47$0.03Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$213.00M+11.0%-$0.24$0.06Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$212.00M+15.5%-$0.41$0.05Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$202.00M+11.5%-$0.29-$0.01Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Myriad Genetics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueGAAPFY2026$780.00M – $790.00M$860.00M – $880.00MLoweredNov 4, 2026
RevenueFY2026$770.00M – $790.00M$860.00M – $880.00MLoweredJul 30, 2026
Revenuenon-GAAPFY2026$860.00M – $880.00M–NewJan 12, 2026
Adjusted Gross Margin %non-GAAPFY202666% – 67%68% – 69%LoweredNov 4, 2026
Adjusted Gross Margin %non-GAAPFY202666% – 67%68% – 69%LoweredJul 30, 2026
Adjusted EBITDAnon-GAAPFY2026$37.00M – $49.00M$37.00M – $49.00MReaffirmedMay 5, 2026
Adjusted EBITDAnon-GAAPFY2026$37.00M – $49.00M–NewFeb 23, 2026

Guidance vs results

The last range Myriad Genetics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2026Revenue$200.00M – $203.00M$200.40MWithin range
Q1 FY2025adjusted EPS-$0.08 – -$0.04-$0.03Above range
Q1 FY2025Revenue$196.00M – $204.00M$196.00MWithin range
Q1 FY2023Adjusted EPS-$0.20 – -$0.18-$0.21Below range
Q1 FY2023EPS (GAAP)-$0.47 – -$0.45-$0.67Below range
Q1 FY2023Revenue$170.00M – $172.00M$181.20MAbove range

Guidance history

Every forecast Myriad Genetics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted Gross Margin %FY202666% – 67%Lowered
Nov 4, 2026RevenueFY2026$780.00M – $790.00MLowered
Jul 30, 2026Adjusted Gross Margin %FY202666% – 67%Lowered
Jul 30, 2026RevenueFY2026$770.00M – $790.00MLowered
May 5, 2026Adjusted EBITDAFY2026$37.00M – $49.00MReaffirmed
May 5, 2026Adjusted Gross Margin %FY202668% – 69%Reaffirmed
May 5, 2026RevenueFY2026$860.00M – $880.00MNew
Feb 23, 2026Adjusted EBITDAFY2026$37.00M – $49.00MNew
Feb 23, 2026Adjusted Gross Margin %FY202668% – 69%New
Feb 23, 2026revenueQ1 FY2026$200.00M – $203.00MNew
Feb 23, 2026RevenueFY2026$860.00M – $880.00MNew
Jan 12, 2026Adjusted EBITDAFY2026$37.00M – $49.00MNew
Jan 12, 2026Adjusted Gross MarginFY202668% – 69%New
Jan 12, 2026RevenueFY2026$860.00M – $880.00MNew
Aug 5, 2025Adjusted EPSFY2025-$0.02 – $0.02Lowered
Aug 5, 2025RevenueFY2025$818.00M – $828.00MLowered
Feb 24, 2025Adjusted EBITDAFY2025$25.00M – $35.00MReaffirmed
Feb 24, 2025adjusted EPSFY2025$0.07 – $0.11Reaffirmed
Feb 24, 2025adjusted EPSQ1 FY2025-$0.08 – -$0.04New
Feb 24, 2025Gross margin %FY202569.5% – 70.5%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Myriad Genetics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. News
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?